• Evonik expects fiscal 2026 adjusted EBITDA in the upper half of its €2 billion–€2.2 billion guidance range.
• Return on capital employed is now forecast above 8%, versus 6.1% in 2025, with roughly 11% targeted by 2029.
• Third-quarter adjusted EBITDA rose 40% year over year to €629 million; the margin reached 16.4%.
• Full-year free cash flow is forecast at roughly €850 million, implying 40% cash conversion.
• The Oxeno divestment is on track for signing in coming months, with the SYNEQT sale process to launch immediately afterward.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evonik Industries AG published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.